Search - tctmd.com

Displaying 1 - 20 of 43

Sort: Relevancy | Date

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Daily News

CMS Greenlights Reimbursement for Renal Denervation Systems

L.A. McKeown

October 29, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2024

Caitlin E. Cox

December 31, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

News Opinion Editor's Corner

What’s Going to Be Hot at TCT 2023

Shelley Wood

October 19, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2023

Caitlin E. Cox

September 04, 2023

News Daily News

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

L.A. McKeown

August 23, 2023

News Daily News

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

L.A. McKeown

August 18, 2023

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2022

Shelley Wood

January 03, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

Shelley Wood

October 03, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Advertisement

What’s Going to Be Hot at AHA 2025?

CMS Greenlights Reimbursement for Renal Denervation Systems

TCTMD’s Top 10 Most Popular Stories for December 2024

August 2024 Dispatch for the CV Team

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Top Endovascular News of 2023

TCTMD’s Top 10 Most Popular Stories for November 2023

What’s Going to Be Hot at TCT 2023

TCTMD’s Top 10 Most Popular Stories for August 2023

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

BP Reduction With Renal Denervation Still Evident a Decade On

TCTMD’s Top 10 Most Popular Stories for December 2022

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

TCTMD’s Top 10 Most Popular Stories for September 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content